AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underway Obe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS) Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press releaseLONDON and GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical...

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; NASDAQ: AYA) (“Aya” or the “Corporation”) today announced its financial and operational results for the first quarter ended March 31, 2026. All amounts are in U.S. dollars unless otherwise noted. Q1 2026 Highlights Financial HighlightsRevenue of $117M, up 247% year-over-year (“YoY”) and up 56% quarter-over-quarter (“QoQ”), driven by higher average net realized silver equivalent (“AgEq”) prices and more AgEq ounces sold, totaling 1.4M. Average net realized silver equivalent price of $82.22/oz, up 158% YoY and 41% QoQ. Net income of $49M (basic EPS of $0.34 and diluted EPS of $0.33), up 600% YoY from net income of $7M (basic and diluted EPS of $0.05) in Q1-2025 and from $18M (basic EPS of $0.13 and diluted EPS of...

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (“LIEN” or the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsTotal gross investment income of $16.7 million Net investment income of $10.0 million, or $0.44 per weighted average share outstanding Total investment portfolio of $364.0 million at fair value, an increase of $30.7 million as compared to the prior quarter Net asset value (“NAV”) per share was $13.33 on March 31, 2026, a $0.03 increase as compared to the prior quarter Board of Directors declared a dividend of $0.34 per share for the quarter ending June 30, 2026, payable on July 10, 2026 to shareholders of record...

Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Updates Scientific Presentations and Publications In March 2026, the results of our Phase 2b trial...

(All amounts in release are in Canadian dollars) OTTAWA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX:CGY), a mission critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, today released its results for the second quarter ended March 31, 2026. “Our second quarter results mark an important inflection point for Calian as we begin to capture the benefits of strengthening demand across the defence sector,” said Patrick Houston, Calian CEO. “Revenue grew 18%, including 12% organic growth, which was achieved through record-setting deliveries and a strong pace of contract signings. This solid top-line performance translated into an 60% increase in adjusted EBITDA1, which significantly outpaced revenue growth and reflects the compounded...

Company Reaffirms Annual Guidance; New Product Innovation Supports Improving Sales Trends Exiting the Quarter GRAPEVINE, Texas, May 14, 2026 (GLOBE NEWSWIRE) — Solo Brands, Inc. (OTCQB: SBDS) (“Solo Brands” or “the Company”), a leading portfolio of lifestyle brands (Solo Stove, Chubbies, ISLE and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three months ended March 31, 2026. “The first quarter reflects meaningful progress in our transformation as we operate Solo Brands with a leaner cost structure, stronger cash discipline, and a sharper focus on profitability,” said John Larson, President and Chief Executive Officer. “While top-line performance remained challenged, particularly within Solo Stove, the decisive actions we’ve taken over the past year have significantly...

SINGAPORE, May 14, 2026 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for AI and Bitcoin mining infrastructure, today released its unaudited financial results for the first quarter ended March 31, 2026. Q1 2026 Financial1 HighlightAll amounts compared to Q1’25 unless otherwise notedTotal revenue was US$188.9 million vs. US$70.1 million. Cost of revenue was US$228.0 million vs. US$74.1 million. Gross loss was US$39.0 million vs. US$4.0 million. Net loss was US$159.5 million vs. net profit of US$105.3 million. Adjusted EBITDA2 was positive US$14.4 million vs. negative US$45.6 million. Cash, cash equivalents and restricted cash were US$297.7 million as of March 31, 2026. Digital assets and digital assets – receivable balance: US$245.0 million as...

 ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C., May 14, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos,” “we” or the “Company”), today announced its financial results for the first quarter ended March 31, 2026, which can be found in the Financial Results section of the Company’s website at https://ir.pelthos.com/financial-info/financial-results. First...

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy and in combination with pembrolizumab for the treatment of R/M HNSCC Announced the appointment of Nelson Azoulay as Chief Business Officer         Expected...

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026 Cross-species nonclinical findings that support skin frataxin levels as a surrogate endpoint for nomlabofusp program published in peer-reviewed journalTopline open label study data to support BLA submission expected in Q2 2026 $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, with projected cash runway into the second quarter of 2027BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2026...